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OBJECTIVE—The response of ventromedial hypothalamic
(VMH) glucose-inhibited neurons to decreased glucose is im-
paired under conditions where the counterregulatory response
(CRR) to hypoglycemia is impaired (e.g., recurrent hypoglyce-
mia). This suggests a role for glucose-inhibited neurons in the
CRR. We recently showed that decreased glucose increases nitric
oxide (NO) production in cultured VMH glucose-inhibited neu-
rons. These in vitro data led us to hypothesize that NO release
from VMH glucose-inhibited neurons is critical for the CRR.
RESEARCH DESIGN AND METHODS—The CRR was evalu-
ated in rats and mice in response to acute insulin-induced
hypoglycemia and hypoglycemic clamps after modulation of
brain NO signaling. The glucose sensitivity of ventromedial
nucleus glucose-inhibited neurons was also assessed.
RESULTS—Hypoglycemia increased hypothalamic constitutive
NO synthase (NOS) activity and neuronal NOS (nNOS) but not
endothelial NOS (eNOS) phosphorylation in rats. Intracerebro-
ventricular and VMH injection of the nonselective NOS inhibitor
N
G-monomethyl-L-arginine (L-NMMA) slowed the recovery to
euglycemia after hypoglycemia. VMH L-NMMA injection also
increased the glucose infusion rate (GIR) and decreased epineph-
rine secretion during hyperinsulinemic/hypoglycemic clamp in
rats. The GIR required to maintain the hypoglycemic plateau was
higher in nNOS knockout than wild-type or eNOS knockout mice.
Finally, VMH glucose-inhibited neurons were virtually absent in
nNOS knockout mice.
CONCLUSIONS—We conclude that VMH NO production is
necessary for glucose sensing in glucose-inhibited neurons and
full generation of the CRR to hypoglycemia. These data suggest
that potentiating NO signaling may improve the defective CRR
resulting from recurrent hypoglycemia in patients using intensive
insulin therapy. Diabetes 59:519–528, 2010
I
ntensive insulin therapy signiﬁcantly reduces the
onset and progression of hyperglycemia-related
complications in patients with type 1 and advanced
type 2 diabetes. However, intensive insulin therapy
also causes a clinically adverse effect: hypoglycemia (1).
Powerful neuroendocrine and autonomic counterregula-
tory mechanisms protect the brain from hypoglycemia
(2,3). These protective mechanisms, known as the coun-
terregulatory response (CRR) to hypoglycemia, involve
the release of hormones (e.g., glucagon, epinephrine) that
restore euglycemia by stimulating hepatic glucose produc-
tion and inhibiting peripheral glucose uptake (3). Although
the physiology of the CRR is well understood, the under-
lying cellular mechanisms by which the brain senses
hypoglycemia and initiates the CRR remain elusive.
During hypoglycemia, central and peripheral glucose
sensors detect declining glucose levels (4). In the brain,
the ventromedial hypothalamus, which includes the arcu-
ate nucleus and the ventromedial nucleus (VMN), is im-
portant in the initiation of the CRR (5–7). This region
contains specialized glucose-sensing neurons (GSNs).
Ventromedial hypothalamic (VMH) GSN electrical activity
is regulated by physiologically relevant changes in extra-
cellular glucose levels (8–11). Glucose-excited neurons
decrease, whereas glucose-inhibited neurons increase,
their input resistance, membrane potential, and action
potential frequency when extracellular glucose is reduced
(10). Many studies suggest that VMH glucose-inhibited
neurons play a critical role in the control of the CRR (4).
For example, the response of VMH glucose-inhibited neu-
rons to decreased glucose is impaired under conditions
where the CRR is impaired (e.g., recurrent hypoglycemia)
(12,13).
Nitric oxide (NO) is a gaseous messenger produced by
NO synthase (NOS). Two classes of NOS have been
identiﬁed in the brain: the inducible NOS (iNOS) and the
constitutive NOS, which includes the neuronal NOS
(nNOS) and endothelial NOS (eNOS) isoforms (14). Hypo-
thalamic NO is involved in the regulation of food intake
and glucose homeostasis (15–18). In support of this, we
have recently shown that VMH glucose-inhibited neurons
produce NO via nNOS in response to decreased extracel-
lular glucose levels (19,20). Therefore, in this study, we
test the hypothesis that NO production by VMH glucose-
inhibited neurons is necessary for the CRR to hypoglyce-
mia. We tested this hypothesis using a combination of in
vivo and in vitro techniques in wild-type rats and mice as
well as in transgenic nNOS and eNOS knockout mice.
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All procedures were approved by the Institutional Animal Care and Use
Committee at the University of Medicine and Dentistry of New Jersey. Adult
male Sprague-Dawley rats were purchased from Charles River. Adult 5- to
8-week-old C57BL/6J wild-type, nNOS knockout (B6.129S4-Nos1
tm1Plh/J), and
eNOS knockout (B6.129P2-Nos3
tm1Unc/J) mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). Animals were housed individually and
maintained on a 12-h light/12-h dark schedule at 22–23°C with ad libitum
access to food and water.
In vivo experiments
Surgical procedures. Rats were anesthetized with sodium pentobarbital (50
mg/kg i.p.; Ovation) and mice, with ketamine/xylazine (80/8 mg/kg i.p.; Bioniche-
Pharma/Lloyd Laboratories). Vascular catheters were surgically implanted in the
left carotid and/or the right jugular vein in rats, and a vascular catheter was
implanted in the right jugular vein in mice. The catheters were ﬁlled with heparin
(10 units/ml) and ﬂushed every other day. Additionally, rats received a stereotaxic
implantation of microinjection cannula guide positioned 1-mm dorsal to the
ventromedial hypothalamus or in the right lateral ventricle according to stereo-
taxic coordinates (VMH cannulation; from bregma: 2.5 mm anterior-posterior,
2.8 mm medial-lateral, and 8.5 mm dorsal-ventral, at an angle of 20°;
intracerebroventricular [ICV] cannulation; from bregma: 1.0 mm anterior-
posterior, 1.4 mm medial-lateral, and 4.0 mm dorsal-ventral). Animals were
allowed 5–7 days to recover from surgery and were handled every day. Animals
that did not recover to their presurgery body weights were excluded from the
study. For probe placement, at the end of each experiment, cannula placement
was veriﬁed by methyl-blue (Sigma) injection.
Experimental procedures. Animals undergoing hyperinsulinemic/hypogly-
cemic clamps were either fasted overnight (rats) or for 5 h (9:00 A.M. to 2:00
P.M.; mice). Two hours before the start of the study, catheters were external-
ized outside the cage to minimize investigator interaction and were connected
to infusion pumps. Starting 30 min before insulin injection (see below), one
group of rats was infused intracerebroventricularly (0.4 l/min, 2 h), whereas
another group was injected in the ventromedial hypothalamus (0.1 l/min, 10
min) with one of the following compounds in artiﬁcial cerebrospinal ﬂuid
(aCSF; containing in mM: 135 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, pH 
7.4): N
G-monomethyl-L-arginine (L-NMMA; 50 mmol/l in aCSF), 1H-[1,2,4]-
oxadiazolo-[4,3-a]quinoxalin-1–1 (ODQ; 0.1 mmol/l in aCSF containing 0.1%
DMSO). The control for L-NMMA was injected with aCSF, whereas the control
for ODQ was injected with DMSO (0.1% in aCSF).
Acute insulin infusion. Rats (100–150 g) were injected with an insulin bolus
(1 unit/kg; regular human insulin; Eli-Lilly) through the jugular catheter 30 min
after ICV or VMH infusion. Blood glucose was monitored every 15 min from
30 to 120 min after insulin infusion via tail prick.
Hyperinsulinemic/hypoglycemic clamp. Starting 30 min after VMH or ICV
infusion, rats (300–350 g) or mice (7–8 weeks old) were injected through the
jugular catheter with an insulin bolus (rats: 0.4 units/kg; mice: 1 unit/kg) to
decrease glycemia to 50 mg/dl within 30–40 min. This time course was used
based on the results of Saberi et al. (21), suggesting that brain versus
peripheral glucose sensors predominate in CRR initiation when blood glucose
decreases rapidly. After this bolus, animals were perfused with insulin at 1.2
units  kg
1  h
1 for 90 (rats) or 120 (mice) min. Glucose (20%) was
co-perfused with insulin to maintain plasma glucose level of 50 mg/dl. The
concentration of blood glucose was measured every 10 min via tail prick. For
clamps carried out in rats, arterial blood samples (500 l) taken from the
carotid catheter were collected at 0, 30, 60, and 90 min for subsequent
measurement of plasma glucagon, epinephrine, and norepinephrine. Glu-
cocorticoid levels were not measured because they are not an essential aspect
of the recovery from an acute hypoglycemic challenge (for review, see [22]).
For glucagon, 250 l of blood was collected in chilled tubes containing EGTA
(1.6 mg/ml; Sigma) and aprotinin (250 KIU/ml; Sigma). For catecholamines,
blood was collected in chilled tubes containing reduced glutathione (1.2
mg/ml; Sigma) and EDTA (1.8 mg/ml; Sigma). After removal of plasma,
erythrocytes from experimental rats were resuspended in an equivalent
volume of sterile NaCl 0.9% and reinfused after each blood sampling to
prevent volume depletion. For mice clamp, trunk blood was collected at the
end of the clamp in chilled tubes containing reduced glutathione (1.2 mg/ml;
Sigma) and EDTA (1.8 mg/ml; Sigma) for plasma epinephrine and norepineph-
rine measurement.
Plasma glucagon and catecholamine determination. Plasma glucagon
concentrations were determined using commercially available radioimmuno-
assay kits (Linco Research). Plasma epinephrine and norepinephrine concen-
trations were analyzed by high-performance liquid chromatography using
electrochemical detection (ESA Biosciences, Acton, MA).
Phosphorylated-NOS Western blot. Rats (100–150 g) were injected with
saline or insulin (2 units/kg, s.c.) and killed 60 min after by an overdose of
sodium pentobarbital (Euthasol, Virbac, Fort Worth, TX). The ventral hypo-
thalamus was quickly harvested, snap frozen, and stored at 80°C. Brain
samples were lysed over ice in lysis buffer (150 mmol/l NaCl, 0.02% sodium
azide, 10 mmol/l HEPES, 50 mmol/l NaF, 0.1% SDS, 0.5% deoxycholic acid, 1%
Nonidet P-40, 0.2 mmol/l phenylmethylsulfonyl ﬂuoride, 2 g/ml pepstatin-A, 2
g/ml leupeptin, and 2 g/ml aprotinin). Cytosolic lysate supernatants were
collected by centrifugation at 14,000g for 10 min at 4°C. Protein (15 g) was
electrophoresed and transferred to nitrocellulose membranes. Immunodetec-
tion with primary antibodies was performed for 12 h at 4°C: phosphorylated-
NOS (P-nNOS; nNOS-Ser 1717) 1:5,000 (Millipore), phosphorylated eNOS
(eNOS-Ser 1177) 1:5,000, and nNOS and eNOS 1:2,500 (Cell Signaling). After
washing, secondary antibody (donkey anti-rabbit; Jackson ImmunoResearch)
was added at 1:1,000 for1ha troom temperature. Signals are visualized using
ECL kit (Thermo) and quantiﬁed using Scion Image. Results are presented as
percentage of control after normalization to total nNOS/eNOS.
NOS activity. NOS activity was quantiﬁed using the radiodetection kit
(Calbiochem) based on the biochemical conversion of [
3H-]L-arginine to
[
3H-]L-citrulline by NOS. To distinguish Ca
2-dependent constitutive NOS
activity (nNOS  eNOS), from Ca
2-independent iNOS activity, hypothalamic
homogenates were prepared as above and divided into two sets of samples,
one of which omitted calcium in the assay medium for measurement of iNOS
activity.
In vitro experiments
Electrophysiology. Coronal brain slices (250 m) from wild-type and nNOS
knockout mice (5–7 weeks old) were prepared as previously described (8,23).
Brieﬂy, viable neurons were visualized under infrared differential-interference
contrast microscopy (DM LFS microscope; Leica Microsystems). Current
clamp recordings (standard whole-cell conﬁguration) from VMN neurons
were performed using a MultiClamp 700A (Axon Instruments) and analyzed
using pCLAMP9 software. During recording, brain slices were perfused at 10
ml/min with normal oxygenated artiﬁcial cerebrospinal ﬂuid containing (in
mM): 126 NaCl, 1.9 KCl, 1.2 KH2PO4, 26 NaHCO3, 2.4 CaCl2, 1.3 MgCl2, 2.5
glucose; 300–310 mOsM, pH 7.4). Borosilicate pipettes (3–5 M; Sutter
Instrument) were ﬁlled with an intracellular solution containing (in mM): 128
K-gluconate, 10 KCl, 4 KOH, 10 HEPES, 4 MgCl2, 0.5 CaCl2, 5 EGTA, and 2
Na2ATP (pH 7.2; 290–300 mOsM). Membrane potential, action potential
frequency, and input resistance in response to constant hyperpolarizing pulse
(20 pA) were monitored as extracellular glucose level was changed from 2.5
to 0.1 mmol/l as described in ﬁgures.
Cellular imaging. VMH neurons were prepared using a protocol modiﬁed
from Murphy et al. (24,25) (see supplementary data for detailed protocol,
available in an online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09hyphen]0421/DC1). VMH neurons were perfused in a closed
chamber at 0.6 ml/min with oxygenated extracellular solution containing (in
mM): 132 NaCl, 5 KCl, 0.45 KH2PO4, 0.45 NaH2PO4, 1.2 CaCl2, 0.5 MgCl2, 0.4
MgSO4, 5 HEPES, 2.5 glucose (pH 7.3; osmolarity adjusted to 300–310 mOsM)
in the presence of 0.5% membrane potential dye (FLIPR-MPD; Molecular
Devices, Sunnyvale, CA). After 10 min of equilibration, VMH neurons were
perfused with the same extracellular solution containing 0.1 mmol/l glucose
for 15 min followed by 15 min at 2.5 mmol/l glucose. Image acquisition and
analysis were performed as previously described (24,25). Neurons were
considered as glucose-inhibited neurons when their ﬂuorescence intensity
reversibly increased more than 25% in response to 0.1 mmol/l glucose. Data
are expressed in percentage of glucose-inhibited neurons detected per dish.
Hypothalamic NO real-time measurement. Wild-type mice were killed by
decapitation without anesthesia. The hypothalamus was quickly harvested
and maintained in 200 l Krebs-Ringer oxygenated solution containing 2.5
mmol/l glucose at 37°C. A NO-speciﬁc amperometric probe (ISO-NOPF100;
World Precision Instruments [WPI], Sarasota, FL) was implanted directly in
the tissue and NO release was monitored. The hypothalamus was exposed to
the following sequence of glucose concentrations (15 min each): 2.5, 0.1, and
2.5 mmol/l. The concentration of NO gas in the tissue was measured in real
time with the data acquisition system LabTrax (WPI) connected to the free
radical analyzer Apollo1000 (WPI). Data acquisition and analysis were per-
formed with DataTrax2 software (WPI). The NO-speciﬁc amperometric probe
was calibrated as previously described (26).
Data analysis. All data are presented as mean  SEM. Statistical analysis
was performed using Graphpad Prism 4.0 by two-way ANOVA followed by
Bonferroni post hoc test, one-way ANOVA followed by Dunnett post hoc test,
or unpaired t test as described in the ﬁgure legends. P  0.05 indicates
statistical signiﬁcance.
RESULTS
Hypoglycemia activates ventral hypothalamic nNOS.
We have previously shown that decreased glucose concen-
tration increases NO production in cultured VMH glucose-
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(20). To conﬁrm that decreased glucose increases hypo-
thalamic NO production, we performed amperometric
measurement of NO release in hypothalamic chunks ex
vivo using an NO-sensitive electrode. As shown in Figure
1, decreased glucose from 2.5 to 0.1 mmol/l signiﬁcantly
increases the amplitude (3.5-fold; P  0.05) and frequency
(2.1-fold; P  0.05) of NO release. NO release returned to
baseline when extracellular solution was subsequently
raised to 2.5 mmol/l glucose (Fig. 1).
To provide in vivo evidence that hypoglycemia increases
hypothalamic NO production, constitutive (nNOS and
eNOS) and inducible (iNOS) activity was determined in
ventral hypothalamus from rats 60 min after insulin injec-
tion. Insulin-hypoglycemia signiﬁcantly increased consti-
tutive NOS activity by 1.45  0.11-fold. iNOS activity was
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FIG. 1. Decreased glucose increases VMH NO release. A: Representative trace of ex vivo amperometric measurements of NO release from mouse
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was not changed in insulin-induced hypoglycemia treated
rats versus control (data not shown). To determine
whether nNOS or eNOS is primarily responsible for
hypoglycemia-induced hypothalamic NO production,
Western blots against the phosphorylated nNOS and
eNOS forms were performed. nNOS phosphorylation
was signiﬁcantly increased by 7.26  0.36-fold, whereas
eNOS phosphorylation was not changed (Fig. 2B), sug-
gesting that nNOS activation was responsible for in-
creased VMH constitutive NOS activity during insulin-
induced hypoglycemia. These data strongly suggest that
insulin-induced hypoglycemia stimulates nNOS-derived
VMH NO production.
Inhibition of VMH NO signaling impairs the CRR to
hypoglycemia. We ﬁrst evaluated the effect of brain NO
on the counterregulatory response to acute insulin-in-
duced hypoglycemia. As shown in Fig. 3, rats infused with
the nonselective NOS inhibitor L-NMMA either intracere-
broventricularly or into the ventromedial hypothalamus
showed signiﬁcantly lower glycemia at 60 and 90 min after
insulin injection compared with control. Many of the
effects of NO are mediated by its receptor, soluble guany-
lyl cyclase (sGC) (14). Inhibition of VMH sGC with ODQ
decreased the glycemia at 45, 60, 90, and 120 min after
insulin injection (Fig. 3B).
To conﬁrm that VMH NO production is involved in
the CRR, we performed hyperinsulinemic/hypoglycemic
clamps (5,6,21,27). During the hypoglycemic clamp, blood
glucose was decreased to similar levels in control (52 
1.1 mg/dl) and treated (54  1.0 mg/dl) animals (Fig. 4).
Administration of the nonselective NOS inhibitor L-NMMA
in the ventromedial hypothalamus signiﬁcantly increased
the glucose infusion rate (GIR) necessary to maintain the
hypoglycemia plateau (Fig. 4). Changes in GIR were
associated with signiﬁcant decreases in epinephrine levels
at 60 and 90 min in L-NMMA–treated animals (Fig. 4).
Glucagon (Fig. 4) and norepinephrine (data not shown)
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activity from rats injected subcutaneously with saline (control, n  6) or insulin (2 units/kg; n  6) 60 min after injection. B: Representative
Western blot (left panel) of ventral hypothalamic total nNOS, phosphorylated nNOS (P-nNOS), total eNOS, and P-eNOS from control or
insulin-treated rats injected subcutaneously with saline (n  5) or insulin (n  5) 60 min after injection. The right panel shows the quantiﬁcation
of the ratio between P-nNOS or P-eNOS and total nNOS or eNOS, respectively. Data are means  SEM and represented as percentage of saline
where the control group was considered to be 100%. *P < 0.05 vs. control (unpaired t test).
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these data show that the VMH NO-sGC signaling pathway
is necessary for the full generation of the sympathoadrenal
response to hypoglycemia.
VMH nNOS is involved in the CRR to hypoglycemia.
To conﬁrm that VMH nNOS derived-NO is involved in
the CRR, we performed hyperinsulinemic/hypoglycemic
clamps in wild-type, nNOS, and eNOS knockout mice. The
GIR required to maintain the hypoglycemic plateau over
the last 30 min was signiﬁcantly higher in nNOS knockout
and lower in eNOS knockout mice compared with wild
type (wild type: 17.4  1.6 mg  kg
1  min
1; nNOS: 31.1 
1.7 mg  kg
1  min
1; eNOS: 12.8  1.1 mg  kg
1  min
1;
P  0.05; Fig. 5B). At the end of the clamp, epinephrine
levels were signiﬁcantly reduced in the nNOS knockout
compared with wild-type or eNOS knockout mice (Fig.
5C). There was no difference in plasma norepinephrine
levels between groups (data not shown). Because the
initial blood glucose level was lower in nNOS knockout
than wild-type mice (nNOS knockout: 136  6.4 mg/dl
versus wild type: 179  7.5 mg/dl; P  0.05), we measured
plasma insulin and liver glycogen content in another group
of mice after 5-h fast. Neither plasma insulin nor liver
glycogen concentration was different between nNOS
knockout and wild-type mice (insulin: wild type: 0.58  0.2
versus nNOS: 0.52  0.1 ng/ml; glycogen: wild type: 23.5 
2.8 versus nNOS: 24.7  5.3 mg/g of liver; n  4; P 	 0.05).
These data show that NO produced speciﬁcally by the
nNOS isoform is necessary for the full generation of the
CRR.
nNOS is necessary for glucose sensing by VMH glu-
cose-inhibited neurons. Data from our laboratory and
others suggest that VMN GSNs play a role in sensing
hypoglycemia and initiating the CRR (9,13,27–32). Because
we showed above that the CRR is impaired in nNOS
knockout mice, we wanted to determine whether the
glucose sensitivity of GSNs is also impaired. We used
whole-cell current clamp recording techniques to measure
the membrane potential, action potential frequency (APF),
and input resistance of VMN neurons in response to
decreased glucose levels from 2.5 to 0.1 mmol/l in wild-
type and nNOS knockout mice. In wild-type mice, three
neurons (3 of 36, 8%) were identiﬁed as glucose-excited
neurons by a decrease in their membrane potential, APF,
and input resistance in response to 2.5–0.1 mmol/l glucose
decrease, whereas 11 neurons (11 of 36, 30%) increased
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sponse to decreased glucose and were identiﬁed as glu-
cose-inhibited neurons (Fig. 6A). In nNOS knockout mice,
four neurons (4 of 25, 16%) were identiﬁed as glucose-
excited neurons (Fig. 6B). In contrast, no glucose-inhib-
ited neurons (0 of 25) were found in nNOS knockout mice
VMN. Results are summarized in Fig. 6C. We conﬁrmed
these electrophysiology data using a membrane potential
sensitive dye in cultured VMH neurons. Whereas 13.0 
1.2% of VMH neurons were glucose-inhibited neurons in
wild-type mice (14 dishes; 1,352 neurons; 7 mice), only
2.4  0.6% were glucose-inhibited neurons in nNOS knock-
out mice (12 dishes; 961 neurons; 3 mice; P  0.05). These
data suggest that VMH glucose-inhibited neuron glucose
sensing is impaired in nNOS knockout mice.
DISCUSSION
This study conﬁrms that decreased glucose increases VMH
NO production in vivo. Moreover, this study supports our
novel hypothesis that NO production is necessary for the
full generation of the CRR and glucose sensing in VMH
glucose-inhibited neurons. Pharmacological inhibition of
VMH NO signaling decreases blood glucose recovery and
impairs the CRR after hypoglycemia. Interestingly, the
impaired CRR in mice lacking nNOS is associated with an
almost complete loss of VMH glucose-inhibited neurons,
consistent with our recently published data showing that
NO production is required for glucose-inhibited neurons to
sense glucose (24). We have previously shown that VMH
glucose-inhibited neurons are less sensitive to decreased
glucose under conditions where the CRR is also impaired.
These data suggested a role for VMH glucose-inhibited
neurons in the CRR (12,13,28,31,33). Our current data
strengthen the hypothesis that detection of hypoglycemia
by VMH glucose-inhibited neurons is a necessary step in
the full generation of the CRR.
We found previously, using in vitro cellular imaging, that
among cultured VMH neurons only glucose-inhibited neu-
rons produce NO in response to decreased glucose. nNOS,
but not eNOS, mediates NO production in VMH glucose-
inhibited neurons (20). In the present study, we conﬁrm
this ﬁnding by showing that decreased glucose increases
VMH NO release using an NO-sensitive electrode. More-
over, insulin-induced hypoglycemia in vivo increases VMH
NOS activity and nNOS phosphorylation. Because insulin
increases nNOS-derived NO production in cultured VMH
neurons (20), insulin injection may contribute to the
increased VMH NO production during this clinically rele-
vant form of hypoglycemia. These data strongly support
our hypothesis that nNOS activation during insulin-in-
duced hypoglycemia induces VMH NO production in vivo.
Cabou et al. (16) recently suggested that cerebral insulin
injection during euglycemia increases hypothalamic NO
production through eNOS. Insulin-induced hypoglycemia
did not increase eNOS activity in our study. Moreover,
because Cabou et al. did not evaluate nNOS activity, they
did not rule out a role for this NOS isoform in response to
cerebral insulin injection. It is possible that prolonged
hyperinsulinemia and/or recurrent episodes of insulin-
induced hypoglycemia further increase VMH NO produc-
tion through a combined increase in nNOS and eNOS
activity.
What is the role of VMH NO production in energetic
homeostasis during energy deﬁcit? One putative function
for VMH NO production is to increase cerebral blood ﬂow,
leading to increased local nutrient availability. Human and
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associated with increased cerebral blood ﬂow in many
brain areas including the hypothalamus (34–36). For ex-
ample, Page et al. (37) recently showed that decreased
blood glucose increased hypothalamic blood ﬂow prior to
the release of CRR hormones. One of the main physiolog-
ical functions of NO is related to the vascular system. The
role of eNOS-mediated NO production in peripheral va-
sorelaxation is well established (38). One of the unique
features of NO as a neurotransmitter is the ability to
diffuse across cell membranes (14). Thus, although we did
not see an increase in eNOS activity in our studies, NO
produced in VMH glucose-inhibited neurons may diffuse to
adjacent vascular smooth muscle cells lining cerebral
vasculature and cause vasodilatation. However, we think
that this is unlikely because Horinaka et al. (39) and
Paulson (40) showed that increased cerebral blood ﬂow in
response to hypoglycemia was NO independent. These
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does not play a role in blood ﬂow regulation. This is
consistent with other studies that suggest a role for the

-adrenergic receptor and/or the ATP-sensitive K
 chan-
nel (KATP) in hypoglycemia-induced increases in cerebral
blood ﬂow (41,42).
Another function of VMH NO production is through the
CRR. We used two complementary approaches to show
that VMH NO production is a physiologically required step
in the full generation of the CRR. First, inhibition of VMH
NO production slows down the recovery to euglycemia in
response to acute insulin-induced hypoglycemia. Although
this is the most physiological evaluation of the CRR, it is
difﬁcult to reliably compare the levels of counterregula-
tory hormones between treatments due to variation in the
actual degree of hypoglycemia. Thus, we also used the
“gold standard” technique for studying the CRR: hyperin-
sulinemic/hypoglycemic clamps. Here we found that VMH
NOS inhibition increases the GIR and decreases epineph-
rine production during hypoglycemic clamps. Moreover,
the GIR is signiﬁcantly greater and epinephrine production
lower in nNOS knockout versus wild-type mice. These
data conﬁrm our hypothesis that VMH NO plays an impor-
tant role in the control of the CRR. However, it is also clear
that the CRR was not completely abolished by either
L-NMMA injection or in the nNOS knockout mice. These
ﬁndings are consistent with parallel regulation of the CRR
by other central or peripheral glucose sensors. Finally,
both eNOS and nNOS knockout mice exhibit insulin
resistance (18,43). In eNOS knockout mice, there was a
decrease in the GIR to maintain the hypoglycemic plateau
that may reﬂect insulin resistance (18,43). The milder
insulin resistance in nNOS knockout mice probably did
not affect the GIR due to the high insulin concentration
used for the hypoglycemic clamp.
The next step was to explore the molecular and cellular
mechanisms by which VMH NO production contributes to
the CRR. Our previous studies suggested a role for VMN
glucose-inhibited neurons in the generation of the CRR
because their response to decreased glucose is impaired
when the CRR is impaired (12,13,28,31,33). We have re-
cently shown that NO production via nNOS is necessary for
VMN glucose-inhibited neurons to depolarize in response to
decreased glucose (24). In the present study, VMH glucose-
inhibited neurons were not detected in nNOS knockout mice
in response to decreased extracellular glucose from 2.5 to 0.1
mmol/l. This glucose concentration decrease, although sup-
raphysiologic, was necessary because we have previously
shown that recurrent episodes of hypoglycemia decrease
the response of VMH glucose-inhibited neurons to de-
creased glucose. In fact, after recurrent hypoglycemia the
response of VMH glucose-inhibited neurons to a glucose
decrease from 2.5 to 0.5 mmol/l was almost undetectable;
however their response to a glucose decrease from 2.5 to
0.1 mmol/l was intact (13). Thus, using a glucose decrease
to 0.1 mmol/l suggests that functional VMH glucose-inhib-
ited neurons are almost absent in nNOS knockout mice.
The CRR was also impaired in nNOS knockout mice.
These data reinforce our hypothesis that activation of
VMH glucose-inhibited neurons in response to decreased
glucose is critical for the full generation of the CRR.
Restoration of VMH NO expression in nNOS knockout
mice would lend further strength to this conclusion.
However, the effects of NO are highly dependent on the
localization of intracellular NO production, which, in turn,
is highly dependent on intracellular NOS localization (14).
Overexpressing nNOS or injecting NO donors into the
ventromedial hypothalamus of nNOS knockout mice
would not mimic physiological NO production and could
lead to difﬁculties in data interpretation. Our data suggest
also that the NO receptor sGC mediates the effect of VMH
NO on the CRR. sGC is expressed in all VMH neurons
including glucose-inhibited neurons (20). Cyclic guanosine
monophosphate produced by sGC has been shown to
modulate neuronal activity (17,44). Taken together, these
data suggest that decreased glucose depolarizes VMH
glucose-inhibited neurons through NO-sGC signaling and
leads to full generation of the CRR.
FIG. 6. nNOS is necessary for glucose sensing by VMN glucose-inhibited neurons. Representative whole-cell current-clamp recordings of VMN
glucose-excited and glucose-inhibited neurons in brain slices from wild-type (WT) mice (A) or nNOS knockout mice (B). The dotted lines
represent the resting membrane potential. Glucose concentration changes are schematically displayed below each recording. Downward
deﬂections in whole-cell current-clamp recordings represent the membrane voltage responses to constant hyperpolarizing currents. (C) Table
summarizing the number (and %) of VMN glucose-excited (GE), glucose-inhibited (GI), or nonglucose-sensitive (NG) neurons in wild-type or
nNOS knockout mice.
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inhibited neurons are not the only mediator of the CRR
because the CRR is still present, albeit impaired, in the
absence of NO signaling. VMH glucose-excited neurons
are normal in nNOS knockout mice. Moreover, Miki et al.
(30) showed that the CRR was impaired and VMH glucose-
excited neurons were absent in KATP-deﬁcient mice.
Therefore, it is likely that VMH glucose-inhibited and
glucose-excited neurons as well as extrahypothalamic
glucose sensors are needed for the full generation of the
CRR. Interestingly, glucagon but not epinephrine secretion
in response to hypoglycemia was impaired in the KATP-
deﬁcient mice (30). In contrast our data indicate that
inhibition of VMH NO signaling impairs epinephrine but
not glucagon or norepinephrine secretion in response to
hypoglycemia. This suggests that different glucose sensors
may control unique elements of the CRR.
In conclusion, the VMH NO-sGC signaling pathway is a
key component in the generation of the CRR. Moreover,
our data provide strong support for our hypothesis that
VMH glucose-inhibited neurons play a crucial role in the
central detection of hypoglycemia and generation of the
CRR. These data also suggest that potentiating NO signal-
ing may enhance epinephrine secretion and glucose
recovery in diabetic patients exposed to recurrent hypo-
glycemia. The role of NO signaling in epinephrine secre-
tion in response to hypoglycemia is extremely relevant for
patients with type 1 diabetes who lack a glucagon re-
sponse. Thus, the NO-sGC signaling pathway may offer
new therapeutic targets to improve the treatment of pa-
tients with type 1 and advanced type 2 diabetes using
intensive insulin therapy.
ACKNOWLEDGMENTS
This work was supported in part by the Juvenile Diabetes
Research Foundation (X.F. and V.H.R.) and the National
Institutes of Health (2RO1-DK-55619 and 1RO1-DK-64566)
(V.H.R.). X.F. was also supported in part by the Philippe
Foundation.
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. The Diabetes Control and Complications Trial Research Group. The effect
of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl
J Med 1993;329:977–986
2. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose
counterregulation after strict glycemic control of insulin-dependent diabe-
tes mellitus. N Engl J Med 1987;316:1376–1383
3. Cryer PE. Glucose counterregulation in man. Diabetes 1981;30:261–264
4. Routh VH, Song Z, Liu X. The role of glucosensing neurons in the detection
of hypoglycemia. Diabetes Technol Ther 2004;6:413–421
5. Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI. Local
ventromedial hypothalamus glucose perfusion blocks counterregulation
during systemic hypoglycemia in awake rats. J Clin Invest 1997;99:361–365
6. Borg WP, During MJ, Sherwin RS, Borg MA, Brines ML, Shulman GI.
Ventromedial hypothalamic lesions in rats suppress counterregulatory
responses to hypoglycemia. J Clin Invest 1994;93:1677–1682
7. Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI. Local ventrome-
dial hypothalamus glucopenia triggers counterregulatory hormone release.
Diabetes 1995;44:180–184
8. Fioramonti X, Contie ´ S, Song Z, Routh VH, Lorsignol A, Pe ´nicaud L.
Characterization of glucosensing neuron subpopulations in the arcuate
nucleus: integration in neuropeptide Y and pro-opio melanocortin net-
works? Diabetes 2007;56:1219–1227
9. Kang L, Routh VH, Kuzhikandathil EV, Gaspers LD, Levin BE. Physiolog-
ical and molecular characteristics of rat hypothalamic ventromedial nu-
cleus glucosensing neurons. Diabetes 2004;53:549–559
10. Song Z, Levin BE, McArdle JJ, Bakhos N, Routh VH. Convergence of pre-
and postsynaptic inﬂuences on glucosensing neurons in the ventromedial
hypothalamic nucleus. Diabetes 2001;50:2673–2681
11. Wang R, Liu X, Hentges ST, Dunn-Meyhell AA, Levin BE, Wang W, Routh
VH. The regulation of glucose-excited neurons in the hypothalamic arcuate
nucleus by glucose and feeding relevant peptides. Diabetes 2004;53:1959–
1965
12. Powell AM, Sherwin RS, Shulman GI. Impaired hormonal responses to
hypoglycemia in spontaneously diabetic and recurrently hypoglycemic
rats: reversibility and stimulus speciﬁcity of the deﬁcits. J Clin Invest
1993;92:2667–2674
13. Song Z, Routh VH. Recurrent hypoglycemia reduces the glucose sensitivity
of glucose-inhibited neurons in the ventromedial hypothalamus nucleus.
Am J Physiol Regul Integr Comp Physiol 2006;291:R1283-R1287
14. Guix FX, Uribesalgo I, Coma M, Mun ˜oz FJ. The physiology and pathophys-
iology of nitric oxide in the brain. Prog Neurobiol 2005;76:126–152
15. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C,
Pe ´nicaud L, Drucker DJ, Magnan C, Burcelin R. Brain glucagon-like
peptide-1 regulates arterial blood ﬂow, heart rate, and insulin sensitivity.
Diabetes 2008;57:2577–2587
16. Cabou C, Cani PD, Campistron G, Knauf C, Mathieu C, Sartori C, Amar J,
Scherrer U, Burcelin R. Central insulin regulates heart rate and arterial
blood ﬂow: an endothelial nitric oxide synthase-dependent mechanism
altered during diabetes. Diabetes 2007;56:2872–2877
17. Riediger T, Giannini P, Erguven E, Lutz T. Nitric oxide directly inhibits
ghrelin-activated neurons of the arcuate nucleus. Brain Res 2006;1125:
37–45
18. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD. Mice with gene disruption
of both endothelial and neuronal nitric oxide synthase exhibit insulin
resistance. Diabetes 2000;49:684–687
19. Canabal DD, Potian JG, Duran RG, McArdle JJ, Routh VH. Hyperglycemia
impairs glucose and insulin regulation of nitric oxide production in
glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol
Regul Integr Comp Physiol 2007;293:R592-R600
20. Canabal DD, Song Z, Potian JG, Beuve A, McArdle JJ, Routh VH. Glucose,
insulin, and leptin signaling pathways modulate nitric oxide synthesis in
glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol
Regul Integr Comp Physiol 2007;292:R1418-R1428
21. Saberi M, Bohland M, Donovan CM. The locus for hypoglycemic detection
shifts with the rate of fall in glycemia: the role of portal-superior mesen-
teric vein glucose sensing. Diabetes 2008;57:1380–1386
22. Cryer PE. Role of growth hormone in glucose counterregulation. Horm Res
1996;46:192–194
23. Fioramonti X, Lorsignol A, Taupignon A, Pe ´nicaud L. A new ATP-sensitive
K channel-independent mechanism is involved in glucose-excited neu-
rons of mouse arcuate nucleus. Diabetes 2004;53:2767–2775
24. Murphy BA, Fakira KA, Song Z, Beuve A, Routh VH. AMP-activated protein
kinase and nitric oxide regulate the glucose sensitivity of ventromedial
hypothalamic glucose-inhibited neurons. Am J Physiol Cell Physiol 2009;
297:C750-C758.
25. Murphy BA, Fioramonti X, Jochnowitz N, Fakira K, Gagen K, Contie S,
Lorsignol A, Penicaud L, Martin WJ, Routh VH. Fasting enhances the
response of arcuate neuropeptide Y-glucose-inhibited neurons to de-
creased extracellular glucose. Am J Physiol Cell Physiol 2009;296:C746-
C756
26. Knauf C, Prevot V, Stefano GB, Mortreux G, Beauvillain JC, Croix D.
Evidence for a spontaneous nitric oxide release from the rat median
eminence: inﬂuence on gonadotropin-releasing hormone release. Endocri-
nology 2001;142:2343–2350
27. McCrimmon RJ, Fan X, Cheng H, McNay E, Chan O, Shaw M, Ding Y, Zhu
W, Sherwin RS. Activation of AMP-activated protein kinase within the
ventromedial hypothalamus ampliﬁes counterregulatory hormone re-
sponses in rats with defective counterregulation. Diabetes 2006;55:1755–
1760
28. Borg MA, Tamborlane WV, Shulman GI, Sherwin RS. Local lactate perfu-
sion of the ventromedial hypothalamus suppresses hypoglycemic counter-
regulation. Diabetes 2003;52:663–666
29. Kang L, Dunn-Meynell AA, Routh VH, Gaspers LD, Nagata Y, Nishimura T,
Eiki J, Zhang BB, Levin BE. Glucokinase is a critical regulator of
ventromedial hypothalamic neuronal glucosensing. Diabetes 2006;55:412–
420
30. Miki T, Liss B, Minami K, Shiuchi T, Saraya A, Kashima Y, Horiuchi M,
Ashcroft F, Minokoshi Y, Roeper J, Seino S. ATP-sensitive K channels in
the hypothalamus are essential for the maintenance of glucose homeosta-
sis. Nat Neurosci 2001;4:507–512
31. Song Z, Routh VH. Differential effects of glucose and lactate on glucosens-
X. FIORAMONTI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 527ing neurons in the ventromedial hypothalamic nucleus. Diabetes 2005;54:
15–22
32. Levin BE, Becker TC, Eiki J, Zhang BB, Dunn-Meynell AA. Ventromedial
hypothalamic glucokinase is an important mediator of the counterregula-
tory response to insulin-induced hypoglycemia. Diabetes 2008;57:1371–
1379
33. McCrimmon RJ, Song Z, Cheng H, McNay EC, Weikart-Yeckel C, Fan X,
Routh VH, Sherwin RS. Corticotrophin-releasing factor receptors within
the ventromedial hypothalamus regulate hypoglycemia-induced hormonal
counterregulation. J Clin Invest 2006;116:1723–1730
34. Bryan RM, Jr, Eichler MY, Johnson TD, Woodward WT, Williams JL.
Cerebral blood ﬂow, plasma catecholamines, and electroencephalogram
during hypoglycemia and recovery after glucose infusion. J Neurosurg
Anesthesiol 1994;6:24–34
35. Bryan RM, Jr, Hollinger BR, Keefer KA, Page RB. Regional cerebral and
neural lobe blood ﬂow during insulin-induced hypoglycemia in unanesthe-
tized rats. J Cereb Blood Flow Metab 1987;7:96–102
36. Kennan RP, Takahashi K, Pan C, Shamoon H, Pan JW. Human cerebral
blood ﬂow and metabolism in acute insulin-induced hypoglycemia. J Cereb
Blood Flow Metab 2005;25:527–534
37. Page KA, Arora J, Qiu M, Relwani R, Constable RT, Sherwin RS. Small
decrements in systemic glucose provoke increases in hypothalamic blood
ﬂow prior to the release of counterregulatory hormones. Diabetes 2009;
58:448–452
38. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiol-
ogy, and pharmacology. Pharmacol Rev 1991;43:109–142
39. Horinaka N, Artz N, Jehle J, Takahashi S, Kennedy C, Sokoloff L.
Examination of potential mechanisms in the enhancement of cerebral
blood ﬂow by hypoglycemia and pharmacological doses of deoxyglucose.
J Cereb Blood Flow Metab 1997;17:54–63
40. Paulson OB. Blood-brain barrier, brain metabolism and cerebral blood
ﬂow. Eur Neuropsychopharmacol 2002;12:495–501
41. Hollinger BR, Bryan RM. Beta-receptor-mediated increase in cerebral
blood ﬂow during hypoglycemia. Am J Physiol 1987;253:H949-H955
42. Horinaka N, Kuang TY, Pak H, Wang R, Jehle J, Kennedy C, Sokoloff L.
Blockade of cerebral blood ﬂow response to insulin-induced hypoglycemia
by caffeine and glibenclamide in conscious rats. J Cereb Blood Flow Metab
1997;17:1309–1318
43. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider
P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance,
hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide
synthase. Circulation 2001;104:342–345
44. Ahern GP, Klyachko VA, Jackson MB. cGMP and S-nitrosylation: two
routes for modulation of neuronal excitability by NO. Trends Neurosci
2002;25:510–517
VMH NO FOR HYPOGLYCEMIA DETECTION AND CRR
528 DIABETES, VOL. 59, FEBRUARY 2010 diabetes.diabetesjournals.org